- Email: [email protected]
Corrigendum to “The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis” [Clin Chim Acta 425 (2013) 163–168]
Clinica Chimica Acta 436 (2014) 352
Contents lists available at ScienceDirect
Clinica Chimica Acta journal homepage: www.elsevier.com/locate/clinchim
Corrigendum
Corrigendum to “The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis” [Clin Chim Acta 425 (2013) 163–168] Sabah Mohamed Alharazy a,⁎, Norella C.T. Kong a, Marlyn Mohd b, Shamsul Azhar Shah c, Abdul Halim Abdul Gafor a, Arbaiyah Ba´in a a b c
Nephrology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia Department of Immunobiology & Microbiology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia Department of Community Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
Please find below the Corrigendum issued in relation to the above entitled paper. The authors would like to apologize for any inconvenience caused. 1. The original uPCI values published in this paper were incorrect; the corrected values are as given below. A. Amend the following text: Page 164: 2.2. Definition of LN activity, line 6 starting “Proteinuria was measured as spot morning urine protein creatinine index (uPCI) and was positive if the value was N1000 mg/mmol (NR ≤ 200)”. With: “Proteinuria was measured as spot morning urine protein creatinine index (uPCI) and was positive if the value was N 100 mg/mmol (NR ≤ 20)”. A. Amend the following text: Page 164: “2.2.4.1. Proteinuria (uPCI) b 500 mg/mmol”. With “2.2.4.1. Proteinuria (uPCI) b 50 mg/mmol”. B. Page 165: “Table 2 Laboratory parameters and SLEDAI-2 K scores between the patient groups.”
DOI of original article: http://dx.doi.org/10.1016/j.cca.2013.07.030. ⁎ Corresponding author. E-mail address: [email protected] (S.M. Alharazy).
http://dx.doi.org/10.1016/j.cca.2014.06.007 0009-8981/© 2014 Elsevier B.V. All rights reserved.
Amend eleventh row. uPCI (NR b 200 mg/mmol creatinine)b 1100 (100–5100) 200 (100–600) b0.001
To read: uPCI (NR b 20 mg/mmol creatinine)b
110 (10–510)
20 (10–50)
b0.001
2. Page 165: “Table 1 Demographic and clinical characteristics of study patients with lupus nephritis.” A. Amend second row starting “Female: no. (%), second column 43 (46.7)” to read: “43 (91.5)”. B. Amend fourth row starting “LN duration (years) median (IQR), second column 7 (1–124)” to read: “7 (1–24)”. 3. Page 167: under Discussion, line 17, starting “These authors also reported that plasma NGAL may be predictive of worsening global and renal disease activity [30]”. Amend reference [30] to read [31] as shown below: “These authors also reported that plasma NGAL may be predictive of worsening global and renal disease activity [31]”.
Contents lists available at ScienceDirect
Clinica Chimica Acta journal homepage: www.elsevier.com/locate/clinchim
Corrigendum
Corrigendum to “The role of urinary neutrophil gelatinase-associated lipocalin in lupus nephritis” [Clin Chim Acta 425 (2013) 163–168] Sabah Mohamed Alharazy a,⁎, Norella C.T. Kong a, Marlyn Mohd b, Shamsul Azhar Shah c, Abdul Halim Abdul Gafor a, Arbaiyah Ba´in a a b c
Nephrology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia Department of Immunobiology & Microbiology, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia Department of Community Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
Please find below the Corrigendum issued in relation to the above entitled paper. The authors would like to apologize for any inconvenience caused. 1. The original uPCI values published in this paper were incorrect; the corrected values are as given below. A. Amend the following text: Page 164: 2.2. Definition of LN activity, line 6 starting “Proteinuria was measured as spot morning urine protein creatinine index (uPCI) and was positive if the value was N1000 mg/mmol (NR ≤ 200)”. With: “Proteinuria was measured as spot morning urine protein creatinine index (uPCI) and was positive if the value was N 100 mg/mmol (NR ≤ 20)”. A. Amend the following text: Page 164: “2.2.4.1. Proteinuria (uPCI) b 500 mg/mmol”. With “2.2.4.1. Proteinuria (uPCI) b 50 mg/mmol”. B. Page 165: “Table 2 Laboratory parameters and SLEDAI-2 K scores between the patient groups.”
DOI of original article: http://dx.doi.org/10.1016/j.cca.2013.07.030. ⁎ Corresponding author. E-mail address: [email protected] (S.M. Alharazy).
http://dx.doi.org/10.1016/j.cca.2014.06.007 0009-8981/© 2014 Elsevier B.V. All rights reserved.
Amend eleventh row. uPCI (NR b 200 mg/mmol creatinine)b 1100 (100–5100) 200 (100–600) b0.001
To read: uPCI (NR b 20 mg/mmol creatinine)b
110 (10–510)
20 (10–50)
b0.001
2. Page 165: “Table 1 Demographic and clinical characteristics of study patients with lupus nephritis.” A. Amend second row starting “Female: no. (%), second column 43 (46.7)” to read: “43 (91.5)”. B. Amend fourth row starting “LN duration (years) median (IQR), second column 7 (1–124)” to read: “7 (1–24)”. 3. Page 167: under Discussion, line 17, starting “These authors also reported that plasma NGAL may be predictive of worsening global and renal disease activity [30]”. Amend reference [30] to read [31] as shown below: “These authors also reported that plasma NGAL may be predictive of worsening global and renal disease activity [31]”.